3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Pemetrexed
9
Cisplatin
9
pembrolizumab
5
defactinib
3
Cyclophosphamide
3
sodium thiosulfate
2
Radiotherapy, Intensity-Modulated
2
Platinum
2
Immunoenzyme Techniques
2
Doxorubicin
2
1,2-diaminocyclohexaneplatinum II citrate
2
vatalanib
1
spartalizumab
1
osimertinib
1
nintedanib
1
liposomal doxorubicin
1
cabozantinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
amatuximab
1
alvocidib
1
aldesleukin
1
X-Rays
1
VS-5584
1
Trabectedin
1
Tetrahydrouridine
1
Specimen Handling
1
Ramucirumab
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Mesothelioma, Malignant
×
amatuximab
×
Clear all
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts